CDKN2A and glioma: Apart from ependymoma, homozygous deletions of CDKN2A have recently been described as adverse prognostic marker for other CNS tumors, including anaplastic IDH-mutant gliomas and BRAF-mutant low-grade gliomas [1, 4, 11].